Pfizer plans to sell $34 billion of its anti-Covid vaccine in 2022, of which it is now selling a version adapted to the Omicron variant, or $2 billion more than expected until then, the pharmaceutical group announced on Tuesday. For this reason, the company has revised upwards its total turnover forecast for the year, which now forecasts between 99,500 and 102,000 million dollars (compared to 98,000 and 102,000 million previously).
Pfizer also expects the dollar’s rise to weigh $700 million more than initially expected in its accounts. On the other hand, it did not modify its sales forecasts for its pill intended to treat Covid-19 (Paxlovid), still forecast at 22,000 million dollars for the whole year.
Quarterly revenue down 6%
In the third quarter, the group saw its turnover fall by 6% to 22.6 billion dollars, in particular due to the postponement to the fourth quarter of deliveries of its anti-Covid vaccine developed with BioNTech (Comirnaty) in the European Union and others. developed countries. and a slowdown in the demand for this vaccine in emerging countries. In the United States, sales of Comirnaty, on the other hand, shot up 83% with the marketing of the new adapted version of Omicron, authorized since the end of August for children over 12 years of age.
Without the vaccine and the anti-Covid pill, Pfizer’s turnover would have increased by 2%. The laboratory saw its net profit increase by 6%, to 8.6 billion dollars. His title took 3% in electronic trading before the opening of the New York Stock Exchange.
The head of the group, Albert Bourla, highlighted the work on vaccines and different treatments for the two products that currently represent the bulk of its turnover. He said that Pfizer plans to launch as many as 19 products in the next 18 months. Albert Bourla reported this Tuesday in particular positive results in a phase 3 clinical trial on the efficacy of a vaccine administered to pregnant women to reduce the risk of respiratory syncytial virus (RSV), responsible for bronchiolitis, in newborns.
Source: BFM TV
